Press releaseGlobe Newswire
Nasus Pharma
NSRX · NYSE American
$3.24+$0.035 (+1.09%)TodayMarket closed ·
Prev close $3.21
Latest news
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- Press releaseGlobe Newswire
Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update
- Press releaseGlobe Newswire
BriefCast Publishes Transcript: Nasus Pharma NS002 Phase 2 Positive Topline Results Webinar Transcript
- NewsVandana Singh
What's Going On With Nasus Pharma Stock On Wednesday
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- NewsAvi Kapoor
Crude Oil Down 4%; Dollar Tree Earnings Top Views
- NewsAvi Kapoor
Dow Jumps Over 500 Points; NY Empire State Manufacturing Index Falls In March
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- Press releaseGlobe Newswire
Nasus Pharma CEO Issues 2025 Letter to Shareholders
- Press releaseGlobe Newswire
Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed
- News
Nasus Pharma Announces Health Canada Has Issued A No-Objection Letter Allowing The Company To Proceed With A Phase 2 Clinical Trial Of NS002, Its Intranasal Epinephrine Powder Being Developed For The Treatment Of Anaphylaxis
- Press releaseGlobe Newswire
Nasus Pharma Announces Approval from Health Canada to Initiate Planned Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder
- Press releaseGlobe Newswire
Nasus Pharma Announces Expanded Agreement to Support Development and Commercialization of NS002 Intranasal Epinephrine Program
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.